Clinical Trials
21 trialsNCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT01760655 2025-10-30
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT03613727 2023-11-07
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Virginia Commonwealth University
Phase 2 Completed
NCT01841333 2022-01-25
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
University of Colorado, Denver
Phase 2 Completed
NCT02763475 2020-10-05
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Phase 2 Completed
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT00001637 2019-12-17
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01392989 2019-05-07
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Stanford University
Phase 2 Completed
NCT00065143 2018-11-07
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038597 2018-10-30
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00611247 2018-06-15
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Completed
NCT01994837 2018-06-06
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 2 Completed
NCT00822094 2017-11-24
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Jazz Pharmaceuticals
Phase 2 Completed
NCT00025662 2016-10-28
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00133367 2016-07-25
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
Phase 2 Completed
NCT00030186 2012-08-23
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00451997 2012-08-01
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00144703 2012-01-26
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00512083 2009-09-25
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
Antisoma Research
Phase 2 Completed
NCT00114764 2008-10-31
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Amgen
Phase 2 Completed